The Jackson Laboratory

The Mouseion at the JAXlibrary
Faculty Research 2018

Faculty Research

3-6-2018

α Cell Function and Gene Expression Are
Compromised in Type 1 Diabetes.
Marcela Brissova
Rachana Haliyur
Diane Saunders
Shristi Shrestha
Chunhua Dai
See next page for additional authors

Follow this and additional works at: https://mouseion.jax.org/stfb2018
Recommended Citation
Brissova, Marcela; Haliyur, Rachana; Saunders, Diane; Shrestha, Shristi; Dai, Chunhua; Blodgett, David M; Bottino, Rita; CampbellThompson, Martha; Aramandla, Radhika; Poffenberger, Gregory; Lindner, Jill; Pan, Fong Cheng; von Herrath, Matthias G; Greiner,
Dale L; Shultz, Leonard D.; Sanyoura, May; Philipson, Louis H; Atkinson, Mark; Harlan, David M; Levy, Shawn E; Prasad, Nripesh;
Stein, Roland; and Powers, Alvin C, "α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes." (2018). Faculty
Research 2018. 55.
https://mouseion.jax.org/stfb2018/55

This Article is brought to you for free and open access by the Faculty Research at The Mouseion at the JAXlibrary. It has been accepted for inclusion in
Faculty Research 2018 by an authorized administrator of The Mouseion at the JAXlibrary. For more information, please contact
Douglas.Macbeth@jax.org.

Authors

Marcela Brissova, Rachana Haliyur, Diane Saunders, Shristi Shrestha, Chunhua Dai, David M Blodgett, Rita
Bottino, Martha Campbell-Thompson, Radhika Aramandla, Gregory Poffenberger, Jill Lindner, Fong Cheng
Pan, Matthias G von Herrath, Dale L Greiner, Leonard D. Shultz, May Sanyoura, Louis H Philipson, Mark
Atkinson, David M Harlan, Shawn E Levy, Nripesh Prasad, Roland Stein, and Alvin C Powers

This article is available at The Mouseion at the JAXlibrary: https://mouseion.jax.org/stfb2018/55

Article

a Cell Function and Gene Expression Are
Compromised in Type 1 Diabetes
Graphical Abstract

Authors
Marcela Brissova, Rachana Haliyur,
Diane Saunders, ..., Nripesh Prasad,
Roland Stein, Alvin C. Powers

Correspondence
marcela.brissova@vanderbilt.edu (M.B.),
al.powers@vanderbilt.edu (A.C.P.)

In Brief
Brissova et al. find that b cells in the type
1 diabetic (T1D) pancreas maintain
several functional and molecular features,
but a cells have impaired glucagon
secretion and an altered gene expression
profile. These findings provide insight into
the mechanism of a cell dysfunction in
T1D.

Highlights
d

d

d

d

T1D b cells appear to maintain several aspects of regulated
insulin secretion
T1D a cells have impaired glucagon secretion and altered
gene expression
Unlike in rodents, a-to-b cell conversion in human T1D is a
very rare event
T1D a cell identity factors improve in a non-autoimmune,
normoglycemic environment

Brissova et al., 2018, Cell Reports 22, 2667–2676
March 6, 2018 ª 2018 The Authors.
https://doi.org/10.1016/j.celrep.2018.02.032

Data and Software Availability
GSE106148

Cell Reports

Article
a Cell Function and Gene Expression
Are Compromised in Type 1 Diabetes
Marcela Brissova,1,13,* Rachana Haliyur,2,13 Diane Saunders,2,13 Shristi Shrestha,3,13 Chunhua Dai,1 David M. Blodgett,4,5
Rita Bottino,6 Martha Campbell-Thompson,7 Radhika Aramandla,1 Gregory Poffenberger,1 Jill Lindner,1
Fong Cheng Pan,8 Matthias G. von Herrath,9 Dale L. Greiner,4 Leonard D. Shultz,10 May Sanyoura,11 Louis H. Philipson,11
Mark Atkinson,7 David M. Harlan,4 Shawn E. Levy,3 Nripesh Prasad,3 Roland Stein,1,8 and Alvin C. Powers1,2,12,14,*
1Department

of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA
of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
3HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
4Department of Medicine, Diabetes Division, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester,
MA, USA
5Math and Science Division, Babson College, Wellesley, MA 02457, USA
6Institute of Cellular Therapeutics, Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, USA
7Department of Pathology, University of Florida Diabetes Institute, College of Medicine, Gainesville, FL, USA
8Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA
9Type 1 Diabetes Center, the La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
10The Jackson Laboratory, Bar Harbor, ME, USA
11Departments of Medicine and Pediatrics, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, IL, USA
12Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA
13These authors contributed equally
14Lead Contact
*Correspondence: marcela.brissova@vanderbilt.edu (M.B.), al.powers@vanderbilt.edu (A.C.P.)
https://doi.org/10.1016/j.celrep.2018.02.032
2Department

SUMMARY

Many patients with type 1 diabetes (T1D) have residual b cells producing small amounts of C-peptide
long after disease onset but develop an inadequate
glucagon response to hypoglycemia following T1D
diagnosis. The features of these residual b cells
and a cells in the islet endocrine compartment are
largely unknown, due to the difficulty of comprehensive investigation. By studying the T1D pancreas
and isolated islets, we show that remnant b cells
appeared to maintain several aspects of regulated insulin secretion. However, the function of T1D a cells
was markedly reduced, and these cells had alterations in transcription factors constituting a and b
cell identity. In the native pancreas and after placing
the T1D islets into a non-autoimmune, normoglycemic in vivo environment, there was no evidence of
a-to-b cell conversion. These results suggest an
explanation for the disordered T1D counterregulatory glucagon response to hypoglycemia.
INTRODUCTION
The events related to type 1 diabetes (T1D) pathophysiology in
humans are poorly defined. For example, we do not understand the initiating trigger for T1D, how b cell loss proceeds,
whether the loss is inevitable or can be abrogated, or the potential for residual b cell recovery. The long-standing view of
T1D pathogenesis was that autoimmune b cell destruction resulted in complete loss of pancreatic insulin secretion. The

improved sensitivity of C-peptide detection as well as studies
using pancreatic specimens have recently led to the realization that many individuals with T1D have insulin-secreting
cells, even 50 years after diagnosis (Keenan et al., 2010;
Oram et al., 2014). Additionally, little is known about the properties of the glucagon-producing a cells in the T1D pancreas
and whether they share the plasticity recently described in
mouse models of profound b cell loss (Chera et al., 2014;
Thorel et al., 2010). Moreover, it is unclear why T1D a cells
have impaired glucagon secretion (Bolli et al., 1983; Gerich
et al., 1973; Sherr et al., 2014), which contributes to hypoglycemia susceptibility.
To comprehensively define the functional and molecular
properties of T1D islets, we used an approach that allows
study of the pancreas and isolated islets from the same organ
donor. Our findings show that remnant b cells appeared to
maintain several features of regulated insulin secretion. In
contrast, glucagon secretion was significantly compromised,
and the levels of essential a cell transcription factors and
their downstream targets involved in a cell electrical activity
were reduced. Moreover, an important b-cell-enriched transcription factor was misexpressed in T1D a cells. These results provide insight into the functional and molecular profile
of a cells in T1D.
RESULTS
Procurement of Pancreatic Islets and Tissue from the
Same Organ Donor Allows for Multifaceted Phenotypic
Analysis of T1D Islets
Our methodology for islet isolation and tissue procurement from
the same pancreas allowed coupling of islet functional and
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Table 1. Demographic Information and Phenotype of T1D Donors
Donors

Age
(Years)

1

12

2

13

3 nPOD
case no. 6342

14

T1D Duration
(Years)

Ethnicity/Race

Gender

BMI

3

Caucasian

F

26.6

5

Caucasian

M

19.1

2

Caucasian

F

24.3

Cause
of Death

C-Peptide
(ng/mL)

High-risk HLAa

AutoAb

anoxia

DR3, DQ2

mIAA

anoxia

DR4, DQ2, DQ8

IA2A, mIAA

<0.02

NA

anoxia

DR4

IA2A, mIAA

0.26

9.2

0.43

NA

<0.02

6.6

0.05

HbA1Cb
9.8

4

20

7

Caucasian

M

25.5

anoxia

DR4, DQ2, DQ8

IA2A

5 nPOD
case no. 6323

22

6

Caucasian

F

24.7

anoxia

DR3, DR4, DQ2

GADA, IA2A

6

27

17

Caucasian

M

18.5

anoxia

DR4, DQ2, DQ8

ND

<0.02

NA

7

30

20

Caucasian

M

29.8

anoxia

DR4, DQ8

ND

<0.02

NA

8

58

31

Caucasian

M

21.7

anoxia

DR4

NA

NA

8.8

The nature of T1D pancreas, organ scarcity, and logistics of organ procurement and processing precluded us from collecting the entire dataset on each
T1D donor. Perifusion, donors nos. 1, 3, 4, and 5; qRT-PCR, donors nos. 1, 4, and 5; islet endocrine cell composition by FACS, donors nos. 1, 4, 5, and
8; histology, donors nos. 1, 2, 5, and 8; islet transplantation, donors nos. 1, 5, and 8; a cell purification and RNA sequencing, donors nos. 3, 6, and 7.
AutoAb, autoantibodies; GADA, glutamic acid decarboxylase autoantibody; HbA1C, hemoglobin A1C; IA2A, autoantibody to transmembrane protein
of the protein tyrosine phosphatase family; mIAA, insulin autoantibody; NA, not available; ND, non-detectable.
a
HLA typing provided by Organ Procurement Organization.
b
HbA1C collected from donor’s redacted medical chart.

molecular analysis with histological assessment of islets in the
native organ (Figure S1A). In this way, we were able to study 5
donors with recent-onset T1D (<10 years of T1D duration) and
3 donors with long-standing T1D (>10 years of T1D duration)
receiving continuous insulin therapy compared to the appropriate non-diabetic controls (Tables 1 and S1). Experimental approaches used for analysis of each T1D donor are indicated in
Table 1 and labeled accordingly in figure legends. Due to clinical
heterogeneity of T1D, we confirmed disease status by DNA
sequencing (Sanyoura et al., 2018) as described in the Supplemental Experimental Procedures. DNA sequencing covering
coding regions and splice junctions of 148 genes associated
with monogenic diabetes did not detect variants associated
with monogenic diabetes (Alkorta-Aranburu et al., 2016;
Table S2). By flow cytometry analysis, recent-onset T1D islets
contained 7-fold more a cells than b cells, and the b cell fraction
was reduced approximately 6-fold compared to normal islets
(Blodgett et al., 2015; Figures S1B–S1D).
T1D b Cells Have Regulated Insulin Secretion
and Express Key Transcriptional Regulators
Next, we analyzed the secretory function of the T1D islets in a
dynamic cell perifusion system and compared it with islets
from normal donors (Kayton et al., 2015). We found that the
few remaining T1D b cells responded to glucose, cyclic AMP
(cAMP)-evoked stimulation, and KCl-mediated depolarization
with a similar pattern as controls (Figures 1A and 1B). The
biphasic glucose-stimulated insulin secretion in islets at T1D
onset was also shown recently by Krogvold and colleagues
(Krogvold et al., 2015). As expected, insulin secretion by T1D islets was diminished when normalized to overall islet cell volume
(expressed in islet equivalents [IEQs]; Figure 1A) due to the
greatly reduced b cell number (Figure S1C). However, insulin
secretion normalized to islet insulin content (reflecting b cell
number) by T1D islets nearly overlapped in terms of magnitude
with the secretory response of controls (Figure 1B). Consistent
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with flow cytometry data in Figure S1C, the T1D b cell population
was 4- to 6-fold less than in control islets when adjusted to
islet insulin content (Figure 1C). Furthermore, the expression of
transcription factors critical for b cell identity PDX1 (Gao et al.,
2014) and NKX6.1 (Taylor et al., 2013) was not changed in
either isolated T1D islets (Figure 1D) or by protein analysis of
the native pancreatic tissue (Figures 1E, 1F, and S2). Even in
the 58-year-old T1D donor with long-standing T1D, these transcription factors were expressed in rare insulin+ cells found scattered in the exocrine parenchyma (Figures 1E, 1F, and S2). However, MAFA (Guo et al., 2013), a transcription factor known to be
required for murine b cell maturation, was reduced in the T1D
islet (Figure 1D), and there were fewer NKX2.2-expressing T1D
b cells compared to controls (Figures 1G and S2), even though
islet NKX2-2 mRNA was unchanged (Figure 1D). These studies
allowed us to directly access multiple pathways of insulin secretion and suggest that the T1D b cells appear to maintain several
functional features of normal b cells, supporting the notion that
T1D is a disease primarily of b cell loss. Due to very few T1D b
cells available for deeper analyses, we focused our efforts on
comprehensive characterization of the most abundant endocrine cell type in T1D islets, the a cell (Figure S1C).
T1D a Cells Are Functionally Impaired and Have Altered
Expression of Transcription Factors Constituting a and b
Cell Identity
Surprisingly, in spite of T1D islets containing 2-fold more a cells
than normal islets (Figure S1C), their glucagon secretion was not
significantly increased compared to controls when normalized to
overall islet cell volume (expressed as IEQs; Figure 2A). The
response was reduced when normalized to islet glucagon content (Figures 2B and 2C) and lacked the appropriate increase
at low glucose following 30-min high glucose inhibition (Figure 2B, inset). Marchetti and colleagues (Marchetti et al., 2000)
observed a similar defect in glucagon secretion in islets isolated
from a single T1D donor 8 months after the disease onset. These

Figure 1. T1D b Cells in Recent-Onset T1D Retain Secretory Properties and Gene Expression Pattern Similar to Normal b Cells
(A and B) Insulin secretion was assessed in islets isolated from donors with recent-onset T1D (n = 4; ages 12–22 years; donors nos. 1, 3, 4, and 5) and compared to
normal controls (n = 7; ages 7–21 years); G 5.6–5.6 mM glucose, G 16.7–16.7 mM glucose, G 16.7 + IBMX 100–16.7 mM glucose + 100 mM isobutylmethylxanthine
(IBMX), G 1.7 + Epi 1–1.7 mM glucose + 1 mM epinephrine, KCl 20–20 mM potassium chloride.
(A) Insulin secretion normalized to overall islet cell volume (expressed as islet equivalents [IEQs]); ****p < 0.0001.
(B) Insulin secretion normalized to islet insulin content; ***p = 0.0005. Data in (A) and (B) were compared by two-way ANOVA.
(C) Insulin content of control (3.873 ± 0.763 ng/IEQ) and T1D islets (1.131 ± 0.660 ng/IEQ); p = 0.0394; data are represented as mean ± SEM.
(D) Expression of b-cell-enriched transcription factors by qRT-PCR in whole T1D islets (n = 3 donors; ages 12–22 years; donors nos. 1, 4, and 5) and controls (n = 3
donors; ages 11–29 years) was normalized to endogenous control and INS expression; ***p < 0.0007.
(E–G) Expression of b-cell-enriched transcription factors in the native pancreatic tissue from donors with recent-onset T1D (n = 2; ages 12–22 years; donors nos. 1
and 5) was compared to 58-year-old donor with 31 years of T1D duration (donor no. 8) and controls (n = 7; ages 8–55 years). The pancreas of 58-year-old T1D

(legend continued on next page)
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functional changes in T1D a cells were accompanied by reduced
mRNA expression of two bona fide a cell regulators ARX (Courtney et al., 2013) and MAFB (Guo et al., 2013) in isolated islets
(Figure 2D). Notably, histological analysis of native tissues further
revealed that most a cells from T1D donors did not express
MAFB and ARX (Figures 2E, 2F, and S3) but did express low
levels of NKX6.1 (Figures 2G and S3), which is normally only
found in b cells (Figures 1G and S2). A similar pattern has been
seen in a mouse model with extreme b cell loss (Chera et al.,
2014; Thorel et al., 2010). To test whether there was evidence
of a-to-b cell conversion in the T1D donor pancreas, we
searched for, but did not find, islet cells co-expressing insulin
and glucagon (data not shown). This observation differs from
the recently described a-to-b cell conversion in a mouse model
of 99% b cell loss (Chera et al., 2014; Thorel et al., 2010).
Non-autoimmune, Normoglycemic Environment Does
Not Promote Conversion of T1D a Cells into b Cells
To determine whether human T1D a cells following extreme b cell
loss can give rise to b cells when placed in a normoglycemic,
non-autoimmune environment, we transplanted islets from the
same T1D donors into immunodeficient Nod-SCID-IL2Rgnull
(NSG) mice (Brissova et al., 2014; Figure 3A). After one-month
engraftment, mice were treated with either PBS or exendin-4
(Dai et al., 2017), a GLP-1 analog reported to promote b cell
maturation or proliferation for an additional 1 month. At the end
of the treatment, in vivo insulin secretion was stimulated by a
bolus of high glucose and arginine. Although a species-specific
assay readily detected a rise in mouse plasma insulin levels,
human insulin was undetectable (data not shown), indicating
the absence of functional human b cells in T1D islet grafts.
Similar to native tissue, graft immunocytochemistry showed
that b cells were very rare and did not detect insulin/glucagon
co-expression (Figure 3B; data not shown). Because there
were no significant phenotypic differences between PBS- and
exendin-4-treated groups, these treatment groups were combined to assess a cell transcription factor expression. After
transplantation, the number of a cells expressing ARX in T1D
islet grafts was greater (Figure 3D) with a decrease in the number
of NKX6.1+ a cells (Figure 3E) compared to a cells in the native
T1D pancreas, suggesting that the normoglycemic, non-autoimmune environment allowed for partial recovery of a cell identity
marker expression.
Genes Critical to a Cell Identity and Function Are
Differentially Expressed between T1D and Control a
Cells
T1D and control islet a cells were purified by fluorescence-activated cell sorting (FACS) (Figure S4A). RNA-sequencing analysis
(RNA-seq) performed on these cells indicated significant differences in the gene expression profiles (Figures 4A, 4B, and
S4B). Ingenuity pathway analysis (IPA) and Gene Ontology

(GO) term analysis (Tables S3 and S4; Figures S4C and S4D)
identified differences in processes associated with protein synthesis and handling, immune-activated signaling, and cell stress
response pathways. Specifically, T1D a cells had increased
expression of genes important in the unfolded protein response
and formation of tight and adhesive junctions. Conversely, T1D a
cells had significantly reduced expression of genes recently
identified by single-cell RNA-seq as a cell enriched, such as
KLHL41, LOXL4, and PTGER3 (Muraro et al., 2016; Segerstolpe
et al., 2016; Figure 4C). Our RNA-seq analysis further confirmed
dysregulated expression of several islet-enriched transcription
factors in T1D a cells, which we initially detected by RT-PCR
in whole islets and at a protein level in pancreatic tissues
(MAFB, ARX, and NKX6-1; Figures 2D–2G and 4C). Among
islet-enriched transcription factors, RFX6, which lies upstream
of MAFB, ARX, and NKX6-1 in endocrine cell differentiation
(Piccand et al., 2014; Smith et al., 2010), had the most reduced
expression (7.2-fold). In mature mouse and human b cells,
RFX6 directly controls expression of P/Q and L-type voltagegated calcium channels (CACNA1A, CACNA1C, and CACNA1D)
and the KATP channel subunit sulfonylurea receptor 1 (ABCC8)
(Chandra et al., 2014; Piccand et al., 2014; Figure 4C) that associates with Kir6.x pore-forming subunits (Winkler et al., 2009).
T1D a cells also had altered expression of potassium and sodium
ion channels, vesicle trafficking proteins, and cAMP signaling
molecules, which collectively point to altered T1D a cell electrical
activity and impaired glucagon exocytosis (Figure 4D).
DISCUSSION
These results show the utility and advantages of an experimental
approach that studies the pancreatic tissue and isolated islets
from the same T1D individual and incorporates the in vitro and
in vivo analysis of islets removed from the autoimmune, hyperglycemic environment. This approach also allowed us to directly
test multiple pathways of hormone secretion and uncouple effects of decreased b cell mass and b cell dysfunction not
possible in clinical studies in vivo. We found that the rare b cells
in the pancreas present not only in recent-onset T1D but also
many years after T1D diagnosis maintained features of regulated
insulin secretion and/or produced key transcriptional regulators
known to play a critical role in the maintenance of b cell fate and
function. In contrast, T1D a cells, while highly abundant, were
functionally impaired. Impaired glucagon secretion by T1D islets
was associated with altered expression of multiple nuclear regulators (e.g., ARX, MAFB, and RFX6) and their downstream targets, suggesting that these changes directly and indirectly
impact glucagon secretory pathways by altering expression of
potassium and sodium ion channels, vesicle trafficking proteins,
and cAMP signaling molecules. Abnormal glucagon secretion is
a common complication of T1D, including impaired counterregulatory response of glucagon to hypoglycemia (Gerich et al., 1973)

donor did not have any insulin+ islets; only rare b cells were found in exocrine parenchyma. T1D b cells (n = 3 donors; ages 12–58 years; donors nos. 1, 5, and 8)
had normal expression of b-cell-enriched transcription factors PDX1 (E) and NKX6.1 (F) but decreased expression of NKX2.2 (G) compared to controls (n = 7
donors; ages 8–55 years); ****p < 0.0001; ns, not significant.
Data in (C)–(G) were compared by two-tailed Student’s t test. Data in (A)–(G) are shown as mean ± SEM. The scale bar in (E) represents 10 mm and also corresponds to (F) and (G). See also Figures S1 and S2.
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Figure 2. T1D a Cells in Recent-Onset T1D Have Reduced Glucagon Secretion and Dysregulated Gene Expression
The same sets of islets shown in Figures 1A and 1B were simultaneously analyzed for glucagon secretion. The same non-diabetic controls were used as Figure 1.
The labeling of islet stimuli is identical to that in Figure 1.
(A) Glucagon secretion normalized to overall islet cell volume (expressed as IEQs); p = 0.2470.
(B) Glucagon secretion normalized to islet glucagon content; ****p < 0.0001. Data in (A) and (B) were compared by two-way ANOVA. Inset shows mean glucagon
response to low glucose following the 30-min inhibition with high glucose.
(C) Glucagon content in control (206 ± 62 pg/IEQ) and T1D islets (362 ± 149 pg/IEQ); p = 0.2831; data are represented as mean ± SEM.
(D) Expression of a-cell-enriched factors by qRT-PCR in whole T1D islets (n = 3 donors; ages 12–22 years; donors nos. 1, 4, and 5) and controls (n = 3 donors; ages
11–29 years) was normalized to endogenous control and GCG expression; ****p < 0.0001; *p = 0.0184.

(legend continued on next page)
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and an inappropriate rise in circulating glucagon in response to a
mixed meal challenge (Sherr et al., 2014). Defects in neural
glucose sensing, impaired islet innervation, or intra-islet insulin
deficiency have been proposed to explain these abnormalities
in glucagon secretion (Mundinger et al., 2016). The current analysis provides a new explanation and molecular mechanism for
the dysregulated glucagon secretion in T1D, namely an intrinsic
a cell defect (Figure 4D). Our observation that the changes in a
cell gene expression partially resolved when T1D islets were
transplanted into a normoglycemic, non-autoimmune environment suggests that interventions might be developed to improve
a cell gene expression and glucagon secretion in T1D.
These data provide insight and raise important questions
about the molecular and functional changes in human T1D
a cells. After massive b cell loss in mice, b cells can be
gradually and partially replenished by a sustained a-to-b
cell reprogramming (Chera et al., 2014; Thorel et al., 2010).
Unlike in mice, the current analysis did not identify cells coexpressing insulin and glucagon in the native pancreas or
after transplantation into a normoglycemic, non-autoimmune
environment, further supporting the notion that a-to-b cell
conversion in humans is a very rare event (Chakravarthy
et al., 2017). Our findings do suggest that T1D a cells have
reduced key molecular regulators (ARX and MAFB) and express a transcription factor, NKX6.1, that is usually b cell
specific, raising the possibility of partial change toward a b
cell phenotype. Perhaps an additional stimulus or multiple
stimuli may be required for human a cell reprogramming.
Lineage-tracing studies of human a cells are needed to
investigate the plasticity of human a cells.
These results stimulate a number of questions about the molecular and cellular changes in T1D islets. Are the a cell
changes the result of the autoimmune attack on the b cells
also affecting a cells, the lack of a cell-b cell contact, the diabetic milieu of hyperglycemia, or reduced intra-islet insulin?
Have the remnant b cells, which have a number of features of
normal b cells, somehow escaped the autoimmunity; do they
comprise a specific subset of b cells (Dorrell et al., 2016); or
do they represent an incomplete regenerative attempt, arising
via de novo neogenesis from facultative pancreas progenitors
(Xu et al., 2008), b replication (Brissova et al., 2014; Cano
et al., 2008; Nir et al., 2007), and/or transdifferentiation of acinar
cells (Zhou et al., 2008) or other islet endocrine cell types, such
as a cells (Chera et al., 2014; Thorel et al., 2010)? Additional
studies of isolated T1D islets and T1D pancreatic tissue are
needed to better understand the phenotype and possible heterogeneity of T1D a and b cells.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures (Resources Table).

Animals
Immunodeficient 10- to 12-week-old NSG male mice were used for human
islet transplantation studies (Brissova et al., 2014; Dai et al., 2016). Animals
were maintained by Vanderbilt Division of Animal Care in group housing in
sterile containers within a pathogen-free barrier facility housed with a 12 hr
light/12 hr dark cycle and access to free water and standard rodent chow.
All animal procedures were approved from by the Vanderbilt Institutional
Animal Care and Use Committees.
Primary Cell Cultures
Primary human islets were cultured in CMRL 1066 media (5.5 mM glucose,
10% FBS, 1% Pen/Strep, and 2 mM L-glutamine) in 5% CO2 at 37 C for
24–72 hr prior to reported studies (Brissova et al., 2014; Dai et al., 2016). No
cell lines were used in this study.
Human Subjects
Pancreata and islets from normal and T1D donors were obtained through a
partnership with the International Institute for Advancement of Medicine
(IIAM), National Disease Research Interchange (NDRI), Integrated Islet
Distribution Program (IIDP), and Network for Pancreatic Organ Donors with
Diabetes (nPOD). Most pancreata from normal donors were processed
either for islet isolation (Balamurugan et al., 2003) or histological analysis
(described below and Table S1). In most T1D pancreatic organs, islets and
tissue specimens were procured from the same organ. For a number of
controls, human islets were obtained through IIDP (Table S1). Donor
demographic information and phenotype of T1D donors is summarized in
Table 1. The Vanderbilt University Institutional Review Board declared
studies on de-identified human pancreatic specimens do not qualify as
human subject research.
Human Pancreatic Islet Procurement
Pancreata from normal juvenile and T1D donors were received within 18 hr
from cold clamp and maintained in cold preservation solution on ice until
processing. Pancreas was then cleaned from connective tissue and fat,
measured, and weighed. Prior to islet isolation, multiple cross-sectional
slices of pancreas with 2- to 3-mm thickness were obtained from the
head, body, and distal tail (Figure S1A). Pancreatic slices were further
divided into four quadrants and then either snap frozen or processed for
cryosections. Tissue specimens processed for cryosections were fixed in
0.1 M PBS containing 4% paraformaldehyde (Electron Microscopy
Sciences) for 3 hr on ice with mild agitation, washed in four changes of
0.1 M PBS over 2 hr, equilibrated in 30% sucrose/0.01 M PBS overnight,
and embedded in Tissue-Plus O.C.T. compound (Fisher Scientific). Pancreatic organs were processed for islet isolation using an approach previously
described (Balamurugan et al., 2003). Briefly, depending on the size of
pancreatic duct, 18G or 22G catheters were inserted into the main pancreatic duct (one catheter toward head and the other one toward tail). Accessory duct and main pancreatic duct were clamped at the points where
sections were collected to prevent leakage of collagenase solution during
infusion. Collagenase solution consisting of collagenase NB1 (1,600 U/isolation; Crescent Chemical), neutral protease NB1 (200 U/isolation; Crescent
Chemical), and DNase I (12,000 U/isolation; Worthington Biochemical
Corporation) was pre-warmed to 28 C and delivered intraductally using a
Rajotte’s perfusion system and then maintained at 37 C for approximately
20 min. The inflated tissue was then transferred to a Ricordi’s chamber
apparatus for combined mechanical and enzymatic digestion, which was
maintained at 36 C for 5–15 min prior to warm and cold collection. The
digest was incubated in cold RPMI media (Mediatech) supplemented with
heat-inactivated 10% fetal calf serum (Life Technologies) for 1 hr on ice.

(E–G) Analysis of native pancreatic tissue for expression of islet-enriched transcription factors. T1D a cells (n = 4 donors; ages 12–58 years; donors nos. 1, 2, 5,
and 8) expressed b cell marker NKX6.1 (G) and lost bona fide a cell markers MAFB (E) and ARX (F) in most T1D a cells compared to controls (n = 7 donors; ages
8–55 years); ****p < 0.0001.
Data in (C)–(G) were compared by two-tailed Student’s t test. Data in (A)–(G) are shown as mean ± SEM. The scale bar in (E) represents 10 mm and also corresponds to (F) and (G). See also Figures S1 and S3.
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Figure 3. T1D a Cells Do Not Show Evidence of a-to-b Cell Reprogramming in Normoglycemic, Non-autoimmune Environment
(A) Islets from donors with recent-onset and long-standing T1D (n = 3 donors; 12–58 years; donors nos. 1, 5, and 8) depicted in Figures 1 and 2 were transplanted
into NSG mice. After 1-month engraftment, mice were treated with either PBS or Ex-4 for an additional 1 month. Representative images of islet grafts are from the
12-year-old individual with 3-year T1D duration (donor no. 1). In control and T1D columns, regions denoted by the dashed line in images on the left (B)–(E) (scale
bar in B is 50 mm) are displayed on the right (scale bar is 10 mm).
(B) Insulin (INS) and glucagon (GCG) double-positive cells were not detected in either type of T1D islet grafts (PBS or Ex-4).
(C–E) As there were no phenotypic differences between PBS and Ex-4 treatment groups, representative images were taken from both cohorts and analyzed for a
cell transcription factor expression. Change in number of GCG+ cells expressing MAFB (C), ARX (D), and NKX6.1 (E) in transplanted T1D islets (TX) relative to
donor’s native pancreas (Panc) is shown. ****p < 0.0001; ns, not significant.
Data in (C)–(E) are shown as mean ± SEM and were compared by two-tailed Student’s t test.

If post-digestion tissue pellet was larger than 2 mL and islets were distinguishable from exocrine tissue by Dithizone staining (Sigma), a purification
step consisting of density gradient (Biocoll; Cedarlane) centrifugation on a
COBE 2991 Cell Processor (Gambro-Terumo) was used to separate islets
from exocrine tissue. Islets were re-suspended in CMRL 1066 medium
(Mediatech) supplemented with 10% heat-inactivated fetal calf serum
(Life Technologies), 100 units/mL penicillin/0.1 mg/mL streptomycin (Life
Technologies), and 2 mmol/L L-glutamine (Life Technologies). On average,
islet-enriched fraction contained from 30,000 (T1D pancreas) to 90,000
IEQs (normal pancreas) with 25%–50% purity. Islets were cultured for

12–24 hr and then shipped from Pittsburgh to Vanderbilt University and/or
University of Massachusetts for further analysis following shipping
protocols developed by the Integrated Islet Distribution Program (IIDP).
Subsequent assays with isolated islets were set up within 24–48 hr of islet
arrival.
Statistical Analysis
To compare global differences in perifusion outcomes in T1D donors and controls, two-way ANOVA with Sidak’s multiple comparisons test was used. Data
were expressed as mean ± SEM. Two-tailed Student’s t test was used for
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Figure 4. Genes Critical to a Cell Function Are Differentially Expressed in T1D a Cells
Transcriptome by RNA-sequencing analysis of purified human a cells from T1D donors (n = 3; ages 14–30 years; donors nos. 3, 6, and 7) and controls (n = 5; ages
26–55 years).
(A) Principal-component analysis (PCA) plot shows clustering of a cell samples from control and T1D donors.
(B) Heatmap of the pairwise correlation between all samples based on the Spearman correlation coefficient. Perfect correlation is indicated by 1.
(C) Genes associated with a cell identity and function are significantly downregulated in the T1D a cells with increased expression of stress response factors and
cell-cell contact proteins. Vertical dotted lines represent point of significance for fold change (FC) = 1.53 threshold analysis; p < 0.05 for all values shown.

(legend continued on next page)
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analysis of statistical significance for two-group comparisons between T1D
donors and controls. A p value less than 0.05 was considered significant. Statistical analysis was performed using GraphPad Prism software. Statistical details of experiments are described in the figure legends, Results section, and
Supplemental Experimental Procedures.
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Contact  for  reagent  and  resource  sharing  
Further  information  and  requests  for  resources  and  reagents  should  be  directed  to  and  will  be  
fulfilled  by  the  lead  contact,  Marcela  Brissova  (marcela.brissova@vanderbilt.edu)  or  Alvin  
Powers  (al.powers@vanderbilt.edu).  
  
DNA  sequencing  
DNA  samples  were  sequenced  using  a  custom  designed  next-generation  sequencing  (NGS)  
targeted  panel  that  includes  148  genes  implicated  in  monogenic  forms  of  diabetes  (neonatal  
diabetes  and  MODY),  insulin  resistance,  lipodystrophy,  obesity,  rare  syndromic  forms  of  
diabetes,  and  diabetes  candidate  genes  (Alkorta-Aranburu  et  al.,  2016).  The  targeted  NGS  
approach  was  based  on  the  SureSelect  enrichment  (Agilent  Technologies)  protocol  followed  by  
MiSeq  Illumina  NGS.  Data  quality  was  assessed  using  FastQC.  Variants  were  called  using  The  
Genome  Analysis  Toolkit  (GATK)  HaploTypeCaller  v3.3  and  assigned  to  the  transcripts  of  
interest.  Variants  were  then  annotated  in  regards  to  their  positions  in  transcripts  of  interest,  
position  relative  to  the  coding  sequence,  consequence  for  the  protein  or  mRNA  and  a  collection  
of  direct  and  indirect  evidentiary  tools  and  databases  including  NCBI  dbSNP,  1000  Genomes  
Project,  Exome  Sequencing  Project  (ESP),  GERP,  Conseq,  PolyPhen-2,  SIFT  and  the  Human  
Gene  Mutation  Database  (HGMD).  All  variants  were  interpreted  according  to  the  guidelines  of  
the  American  College  of  Medical  Genetics.  All  likely  pathogenic  variants  identified  by  NGS  were  
confirmed  by  Sanger  sequencing.  
  
Measurement  of  endocrine  cell  populations    
Islet  dissociation  and  intracellular  antibody  staining  used  a  previously  described  protocol  
(Blodgett  et  al.,  2015).  Anti-insulin  (Gallus  Immunotech),  anti-chicken  allophycocyanin,  (Jackson  
ImmunoResearch),  anti-glucagon  (Sigma-Aldrich)  conjugated  with  Zenon  Pacific  Blue  
(Invitrogen),  and  anti-somatostatin  (LSBio)  conjugated  with  Zenon  Alexa  Fluor  488  (Invitrogen)  
were  used  to  stain  β,  α,  and  δ  cells,  respectively  (Resources  Table).  Dissociated  islet  cell  
preparations  were  analyzed  using  a  BD  Biosciences  FACS  Aria  II  Cell  Sorter  (University  of  
Massachusetts  Medical  School  Flow  Core  Laboratory).  Cellular  debris  was  eliminated  from  islet  
preparations  using  a  forward  scatter  versus  side  scatter  size  gate.    
  
Assessment  of  pancreatic  islet  function  in  vitro  
Function  of  islets  from  T1D  donors  and  normal  controls  (Tables  1  and  S1)  was  studied  in  a  
dynamic  cell  perifusion  system  at  a  perifusate  flow  rate  of  1  mL/min  (Kayton  et  al.,  2015).  The  
effluent  was  collected  at  3-minute  intervals  using  an  automatic  fraction  collector.  Insulin  and  
glucagon  concentrations  in  each  perifusion  fraction  and  islet  extracts  were  measured  by  
radioimmunoassay  (Millipore).    
  
qRT-PCR  of  isolated  pancreatic  islets  
Quantitative  reverse  transcription  polymerase  chain  reaction  (qRT-PCR)  was  performed  using  
the  primer-probe  approach  from  Applied  Biosystems  (Life  Technologies)  with  18S  and  ACTB  
endogenous  controls  using  Minimum  Information  for  Publication  of  Quantitative  Real-Time  PCR  
Experiments  (MIQE)  guidelines  as  described  (Brissova  et  al.,  2014).  All  primers  are  listed  in  
Resources  Table.  Gene  expression  in  recent-onset  T1D  donors  was  compared  to  normal  
controls  (Tables  1  and  S1).  We  were  able  to  detect  INS  mRNA  in  T1D  islets  by  RT-PCR  and  
found  that  it  was  reduced  to  19±7%  compared  to  controls.  
  
  
  

α  cell  sorting  by  flow  cytometry  for  RNA-sequencing  
Human  islets  were  dispersed  using  a  modified  protocol  as  described  previously  (Aamodt  et  al.,  
2016).  Briefly,  0.025%  trypsin  was  used  to  disperse  cells  and  reaction  was  quenched  with  
modified  RPMI  medium  (10%  FBS,  1%  Penn/Strep,  5  mM  glucose).    Cells  were  washed  in  the  
same  medium  and  counted  on  a  hemocytometer,  then  transferred  to  FACS  buffer  (2  mM  EDTA,  
2%  FBS,  1X  PBS).    Indirect  antibody  labeling  was  completed  via  two  sequential  incubation  
periods  at  4C,  with  one  wash  in  FACS  buffer  following  each  incubation.  Primary  and  secondary  
antibodies,  listed  in  Resources  Table,  have  been  characterized  previously  and  used  to  isolate  
high-quality  RNA  from  α  cells  (Dorrell  et  al.,  2016).  Appropriate  single  color  compensation  
controls  were  run  alongside  samples.    Prior  to  sorting,  propidium  iodide  (0.05  ug/100,000  cells;;  
BD  Biosciences,  San  Jose,  CA)  was  added  to  samples  for  non-viable  cell  exclusion.    Flow  
analysis  was  performed  using  an  LSRFortessa  cell  analyzer  (BD  Biosciences),  and  a  FACSAria  
III  cell  sorter  (BD  Biosciences)  was  used  for  FACS.    Analysis  of  flow  cytometry  data  was  
completed  using  FlowJo  10.1.5  (Tree  Star).  
  
Islet  transplantation  and  assessment  of  grafts  
T1D  islets  were  transplanted  into  immunodeficient  10-12  week  old  NOD-scid-IL2rγnull  (NSG)  
male  mice.  Human  islets  from  three  normal  donors  with  an  average  age  of  37  years  (range  from  
20  to  53  years)  and  average  BMI  of  25.1  (range  from  21.7  to  28.2)  were  obtained  through  IIDP  
(Table  S1).  NSG  mice  were  transplanted  beneath  the  renal  capsule  with  500  –  600  normal  or  
T1D  islet  equivalents  (prepared  as  described  above).  Each  set  of  islets  was  transplanted  into  7-
8  mice.  Islets  were  allowed  to  engraft  for  1  month  and  then  mice  were  randomized  for  an  
additional  1-month  treatment  with  either  phosphate  buffered  saline  (PBS)  or  exendin-4  (Ex),  
which  were  administered  using  an  Alzet  minipump  (model  1004  with  a  pump  volume  of  100  µL,  
Durect  Corporation).  Ex-4  (California  Peptide)  was  reconstituted  in  PBS  without  Ca2+  and  Mg2+  
and  loaded  into  Alzet  pump  at  concentration  of  0.9  mg/mL.  Ex-4  in  plasma  was  measured  by  
EIA  (Phoenix  Pharmaceuticals)  and  reached  concentration  of  4.4  ±  0.2  ng/mL  (n=8  mice).  
Insulin  secretion  in  transplanted  human  islets  was  assessed  by  intraperitoneal  administration  of  
glucose  (2  g/kg  of  body  weight)  and  arginine  (2  g/kg  of  body  weight)  prior  to  and  after  Ex-4/PBS  
treatment.  Human  insulin  in  plasma  was  measured  by  species-specific  radioimmunoassay  
(Millipore).    
  
Immunohistochemical  analysis    
Immunohistochemical  analysis  of  pancreas  was  performed  on  serial  5-µm  cryosections  from  
multiple  blocks  from  head,  body  and  tail  regions  as  described  (Brissova  et  al.,  2014).  Kidneys  
bearing  islet  transplants  were  collected  and  then  5-µm  cryosections  from  5-6  different  depths  of  
each  graft  were  labeled  for  immunofluorescence  as  described  (Brissova  et  al.,  2014).  Primary  
antibodies  to  all  antigens  and  their  working  dilutions  are  listed  in  the  Resources  Table.  The  
antigens  were  visualized  using  appropriate  secondary  antibodies  listed  in  the  Resources  Table.  
Tyramide  Signal  Amplification  (Perkin  Elmer)  was  used  to  visualize  ARX  and  NKX2.2  labeling.  
Digital  images  were  acquired  with  a  Zeiss  LSM510  META  laser  scanning  confocal  microscope  
(Carl  Zeiss).    
  
RNA-sequencing  
Sorted  α  cells  (5,000-125,000)  were  added  to  200  μL  lysis/binding  solution  in  the  RNAqueous  
micro-scale  phenol-free  total  RNA  isolation  kit  (Ambion).  Trace  DNA  was  removed  with  TURBO  
DNA-free  (Ambion),  RNA  integrity  was  evaluated  (Agilent  2100  Bioanalyzer;;  control,  8.36±0.22  
RIN,  n=5  donors;;  T1D,  7.97±0.32  RIN,  n=3  donors),  and  high-integrity  total  RNA  was  amplified  
(Ovation  system;;  NuGen  Technologies)  per  standard  protocol  as  described  previously  (Brissova  
et  al.,  2014).  Amplified  cDNA  was  sheared  to  target  200bp  fragment  size  and  libraries  were  

  

prepared  using  NEBNext  DNA  Library  Prep  (New  England  BioLabs).  50bp  Paired  End  (PE)  
sequencing  was  performed  on  an  Illumina  HiSeq  2500  using  traditional  Illumina  methods  
(Malone  and  Oliver,  2011)  to  generate  approximately  50  million  reads  per  sample.  Raw  reads  
were  mapped  to  the  reference  human  genome  hg19  using  TopHat  v2.1  (Trapnell  et  al.,  2009).  
Aligned  reads  were  then  imported  onto  the  Avadis  NGS  analysis  platform  (Strand  life  Sciences)  
and  filtered  based  on  read  quality  followed  by  read  statistics  to  remove  duplicates.  Transcript  
abundance  was  quantified  using  the  TMM  (Trimmed  Mean  of  M-values)  algorithm  (Dillies  et  al.,  
2012;;  Robinson  and  Oshlack,  2010)  as  the  normalization  method.      
  
Quantification  of  cellular  protein  expression  
Histopathology  reviews  were  conducted  on  the  whole  slide  digital  images.  Protein  expression  of  
nuclear  factors  in  α  and  β  cells  was  quantified  using  MetaMorph  7.1  imaging  software  
(Molecular  Devices)  using  manual  cell  counting  (Brissova  et  al.,  2014)  where  an  average  of  
351±73  α  cells  and  861±141  β  cells  were  counted  per  normal  donor  (n=7),  and  average  of  
718±50  α  cells  and  45±17  β  cells  were  counted  per  T1D  donor  (n=4)  for  each  transcription  
factor.  
  
RNA-sequencing  analysis  
Genes  with  normalized  expression  values  less  than  25  were  removed  prior  to  differential  
expression  analysis  between  control  and  T1D  groups.    Fold  change  (cutoff  ≥  ±1.5)  was  
calculated  based  on  p-value  estimated  by  z-score  calculations  (cutoff  0.05)  as  determined  by  
Benjamini  Hochberg  false  discovery  rate  (FDR)  correction  of  0.05  (Benjamini  and  Hochberg,  
1995).  Differentially  expressed  genes  were  further  analyzed  through  Ingenuity  Pathway  Analysis  
(IPA,  Qiagen)  (Figure  S4C,  Table  S3)  and  Gene  Ontology  (GO)  analysis  using  DAVID  v6.8  
(Huang  et  al.,  2009)  (Figures  4B  and  S4D,  Table  S4).  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  

RESOURCES  TABLE    
  
REAGENT  or  RESOURCE  
Antibodies  
Rabbit  anti-ARX  (1:1000)  

SOURCE  

IDENTIFIER  
N/A  

Rabbit  anti-Glucagon  (1:200)  

Beta  Cell  Biology  
Consortium  
(BCBC)/Patrick  
Collombat  
Cell  Signaling  

Mouse  anti-Glucagon  (1:500)  

Abcam  

Mouse  anti-Glucagon-  Pacific  Blue  (1:600;;  flow  
cytometry)  
Rabbit  anti-Insulin-647  (1:65)  
Guinea  pig  anti-Insulin  (1:1000)  
Chicken  anti-Insulin  (1:10;;  flow  cytometry)  
Rabbit  anti-MAFB  (1:3000)  

Sigma-Aldrich  

Mouse  anti-NKX2.2  (1:1000)  
Rabbit  anti-NKX6.1  (1:2000)  
Rabbit  anti-PDX1  (1:5000)  
Goat  anti-PDX1  (1:5000)  
Goat  anti-Somatostatin  (1:500)  
Mouse  anti-Somatostatin-AlexaFluor  488  (1:200;;  flow  
cytometry)  
Mouse  anti-HIC3-2D12  (Hpa3;;  1:200;;  flow  cytometry)  
Mouse  anti-HIC0-4F9-Biotin  (Hpi1;;  1:100;;  flow  
cytometry)  
Donkey  anti-chicken-APC  (1:25;;  flow  cytometry)  
Donkey  anti-goat-Alexa  Flour  647  (1:200)  
Donkey  anti-Guinea  pig-Cy2  (1:500)  
Donkey  anti-Guinea  pig-Cy5  (1:200)  
Donkey  anti-mouse-Cy5  (1:200)  
Donkey  anti-rabbit-Cy3  (1:500)  
Goat  anti-mouse-PE  (1:1000;;  flow  cytometry)  
Streptavidin  BV421  (1:500;;  flow  cytometry)  
Biological  Samples  
Human  Pancreatic  Islets  (control  and  T1D)  
Human  Pancreatic  Tissue  (control  and  T1D)  

  

Cell  Signaling  
Dako  
Gallus  Immunotech  
Gift  from  Roland  Stein,  
Vanderbilt  University  
Developmental  Studies  
Hybridoma  Bank  
BCBC/Palle  Serup  
C.  V.  E.  Wright  
C.  V.  E.  Wright  
Santa  Cruz  
LS  Bio  
Gift  from  Drs.  Philip  
Streeter  and  Markus  
Grompe  
Novus  
Jackson  
ImmunoResearch  
Jackson  
ImmunoResearch  
Jackson  
ImmunoResearch  
Jackson  
ImmunoResearch  
Jackson  
ImmunoResearch  
Jackson  
ImmunoResearch  
BD  Biosciences  
BD  Biosciences  
Integrated  Islet  
Distribution  Program  and  
Rita  Bottino  
Rita  Bottino  

Cat#  2760;;  RRID:  
AB_659831  
Cat#  ab10988;;  RRID:  
AB_297642  
Cat#  G2654;;  RRID:  
AB_259852  
Cat#  9008  
Cat#  A0564  
Cat#  ABI  
Cat#  BL1228  
Cat#  74-5A5;;  RRID:  
AB_531794  
N/A  
N/A  
N/A  
Cat#  sc-7819;;  RRID:  
AB_2302603  
Cat#  LS-C169129-
100  
N/A  
Cat#  NBP1-18872B  
RRID:  AB_2126328  
Cat  #703-136-155  
RRID:  AB_2340360  
Cat  #705-605-003  
RRID:  AB_2340436  
Cat  #706-225-148  
RRID:  AB_2340467  
Cat  #706-175-148  
RRID:  AB_2340462  
Cat  #715-175-151  
RRID:  AB_2340820  
Cat  #711-165-152  
RRID:  AB_2307443  
Cat#  550589  
RRID:  AB_393768  
Cat#  563259  
  
  

Chemicals,  Peptides,  and  Recombinant  Proteins  
Propidium  Iodide  
Exenatide-4  (Ex-4)  
L-Arginine  monohydrochloride  

BD  Biosciences  
California  Peptide  
Sigma  Life  Science  

D-(+)-Glucose  

Sigma  Life  Science  

3-Isobutyl-1-methylxanthine  (IBMX)  

Sigma  Life  Science  

(±)-Epinephrine-hydrochloride    

Sigma-Aldrich  

Potassium  Chloride  

Fisher  Scientific  

Collagenase  NB1  Premium  Grade  
Neutral  Protease  NB1  Premium  Grade  
DNase  I  

Crescent  Chemical  
Crescent  Chemical  
Worthington  Biochemical  
Corporation  
Mediatech  
Cedarlane  
Cedarlane  
Life  Technologies  
Sigma  
Mediatech  
Life  Technologies  
Life  Technologies  
Electron  Microscopy  
Sciences  
Fisher  Scientific  

RPMI  Medium  
Biocoll-Separating  Solution,  Density  1.10  g/mL  
Biocoll-Separating  Solution,  Density  1.077  g/mL  
Fetal  Calf  Serum  
Dithizone  
CMRL  1066  Medium  
Penicillin/Streptomycin  mix  
L-glutamine  
16%  paraformaldehyde  
O.C.T.  compound  
Critical  Commercial  Assays  
Insulin  Radioimmunoassay  
Glucagon  Radioimmunoassay  
RNAqueous-Microkit  

99-595-CM  
Cat#  L6155  
Cat#  L6113  
Cat#  16-140-071  
Cat#  D5130  
Cat#  99-663-CV  
Cat#  15140163  
Cat#  2030-081  
Cat#  15710  
Cat#  4585  

Millipore  
Millipore  
Invitrogen  by  Thermo  
Fisher  Scientific  
Phoenix  Pharmaceuticals  
Millipore  

RI-13K  
GL-32K  
AM1931  

NCBI  Gene  Expression  
Omnibus  

GEO:  GSE106148  

Mouse:  NOD-scid-IL2rγnull  (NSG)  

Jackson  Laboratory  

https://www.jax.org/st
rain/005557  

Oligonucleotides  
18S  
ACTB  
ARX  
GCG  
INS  
MAFA  
MAFB  
NKX2.2  

Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  
Applied  Biosystems  

Hs99999901_s1  
Hs99999903_m1  
Hs00292465_m1  
Hs00174967_m1  
Hs02741908_m1  
Hs01651425_s1  
Hs00534343_s1  
Hs00159616_m1  

EIA  ELISA  
Human-specific  insulin  radioimmunoassay  
Deposited  Data  
RNA-seq  data  for  FACS  purified  human  control  and  
T1D  alpha  cells    
Experimental  Models:  Organisms/Strains  

  

Cat#  556463  
Cat#  507-77  
Cat#  A6969-25G;;  
CAS:  001119-34-2  
Cat#  G7528-1KG;;  
CAS:  50-99-7  
Cat#  I5879-1G;;  CAS:  
28822-58-4  
Cat#  E4642-5G;;  
CAS:  329-63-5  
Cat#  BP366-500;;  
CAS:  7447-40-7  
Cat#  17455.03  
Cat#  30301.02  
Cat#  LS006333  

EK-070-94  
HI-14K  

NKX6.1  
PDX1  
Software  and  Algorithms  
TopHat  (v2.1)  

Applied  Biosystems  
Applied  Biosystems  

Hs00232355_m1  
Hs00236830_m1  

Trapnell,  2009  

Avadis  NGS  analysis  Platform  

Strand  life  Sciences,  
Bengaluru  

Trimmed  Mean  of  M-values  (TMM)  algorithm  
DAVID  (v6.8)  

Dillies,  2012  
Robinson,  2010  
Huang,  2009  

http://tophat.cbcb.um
d.edu/    
RRID:  SCR_013035  
http://www.avadis-
ngs.com    
RRID:  SCR_000644  
  

Ingenuity  Pathway  Analysis  (IPA)  
Prism  v.7.0  

Qiagen  
Graphpad  Software  

MetaMorph  7.1    

Molecular  Devices  

Zeiss  LSM  Imaging  Software  (confocal)  

Carl  Zeiss  

Genome  Analysis  Toolkit  (GATK)  HaploTypeCaller  
v3.3  

Broad  Institute  

Other  
Zenon  Kit  Alexa  Fluor  488  
Zenon  Kit  Pacific  Blue  
Tyramide  Signal  Amplification  

  
  
  
  
  
  
  
  
  
  
  
  
  

  

Invitrogen  
Invitrogen  
Perkin  Elmer  

http://david.abcc.ncifc
rf.gov/    
RRID:  SCR_001881  
RRID:  SCR_008653  
https://www.graphpad
.com;;    
RRID:  SCR_002798  
https://www.molecula
rdevices.com;;  RRID:  
SCR_002368  
https://www.zeiss.co
m;;  
RRID:  SCR_014344  
https://software.broad
institute.org/gatk/;;  
RRID:  SCR_001876  
Cat#  Z25002  
Cat#  Z25041  
Cat#  NEL744001KT  

Figure  S1.  Related  to  Figures  1  and  2.  Composition  and  morphology  in  T1D  islets.  (A)  Schematic  of  islet  isolation  
and  tissue  procurement  from  the  same  pancreas.  Prior  to  islet  isolation,  multiple  cross-sectional  slices  of  pancreas  with  2-
3  mm  thickness  were  obtained  from  the  head,  body  and  tail.  Pancreatic  slices  were  further  divided  into  four  quadrants  (A,  
B,  C,  D)  and  processed  for  histology.  (B)  Pancreatic  islets  procured  from  a  12-year-old  individual  with  3-year  T1D  duration  
(donor  #1).  (C)  Endocrine  cell  populations  in  dispersed  isolated  islets  from  3  donors  (#1,4,5)  with  recent-onset  T1D  
contained  10.8±0.5%  β  cells,  77.1±6.3%  α  cells,  and  12.0±5.9%  δ  cells.  The  donor  with  longstanding  T1D  (donor  #8)  had  
0%  β  cells,  95%  α  cells,  and  5%  δ  cells.  For  comparison,  islets  from  normal  individuals  (n=28)  with  average  age  of  36±2  
years  (range  16  –  63  years)  assessed  by  this  approach  had  53.4±2.6%  β  cells,  38.5±2.7%  α  cells,  and  7.5±0.9%  δ  cells  
(Blodgett  et  al.,  2015).  (D)  Morphology  of  T1D  islets  in  the  native  pancreas.  On  average  250  islets  from  pancreatic  head,  
body  and  tail  of  each  T1D  donor  were  analyzed  for  the  presence  of  β  cells.  An  islet  was  categorized  as  insulin+  even  if  it  
had  only  one  insulin-positive  cell.  The  number  of  insulin+  islets  varied  in  4  donors  (#1,3,4,5)  with  recent-onset  T1D  
(17.8±15.5%),  but  no  insulin+  islets  were  found  in  the  pancreatic  sections  of  our  longstanding  cases  (donors  #6,7,8).  If  
donors  had  insulin+  islets,  representative  islets  are  displayed  in  row  1.  INS–insulin,  GCG–glucagon,  SOM–somatostatin.  
Scale  bar  is  50  µm.  

  

Figure  S2.  Related  to  Figure  1.  Expression  pattern  of  PDX1,  NKX6.1,  and  NKX2.2  in  T1D  β  cells.  Expression  of  β  
cell-enriched  transcription  factors  in  the  native  pancreatic  tissue  from  donors  with  recent-onset  T1D  (donors  #1,5)  was  
compared  to  58-year-old  donor  with  31  years  of  T1D  duration  (donor  #8)  and  controls.  INS–insulin,  GCG–glucagon,  
SOM–somatostatin.  Regions  denoted  by  the  dashed  line  in  panels  E’–  G’  are  displayed  in  panels  E  –  G  in  Figure  1,  
respectively.  Scale  bar  in  E’  is  50  µm  and  also  corresponds  to  panels  F’  and  G’.  

  

Figure  S3.  Related  to  Figure  2.  Expression  pattern  of  MAFB,  ARX,  and  NKX6.1  in  T1D  α  cells.  Expression  of  α  cell-
enriched  transcription  factors  in  the  native  pancreatic  tissue  from  donors  with  recent-onset  T1D  (donors  #1,2,5)  was  
compared  to  58-year-old  donor  with  31  years  of  T1D  duration  and  controls  (donor  #8).  GCG–glucagon,  SOM–
somatostatin.  Regions  denoted  by  the  dashed  line  in  panels  E’–G’  are  displayed  in  panels  E–G  in  Figure  2,  respectively.  
Scale  bar  in  E’  is  50  µm  and  also  corresponds  to  panels  F’  and  G’.    

  

  

  
  
  
Figure  S4.  Related  to  Figure  4.  Transcriptome  analysis  of  purified  human  α  cells  by  RNA-sequencing.  (A)  Gating  
strategy  for  sorting  of  dispersed  human  islet  cells  by  Fluorescence  Activated  Cell  Sorting  (FACS).  Cell  debris  was  
excluded  by  forward  scatter  (FSC)  and  side  scatter  (SSC),  single  cells  were  identified  by  SSC-H  v.  SSC-A  plot,  and  non-
viable  cells  were  excluded  using  Propidium  Iodide  (PI).  The  α  cell  population  was  isolated  based  on  double  positivity  for  
HIC3-2D12  (Hpa3)  and  HIC0-4F9  (Hpi1)  antibodies.  (B)  Volcano  plot  displays  transcripts  differentially  expressed  between  
control  and  T1D  samples  (donors  #3,6,7)  that  reached  statistical  significance  (upregulation:  red;;  downregulation:  green).  
Differential  expression  between  the  two  sample  sets  was  calculated  on  the  basis  of  FC  (≥1.5)  with  a  <0.05  p-value  cut-off  
for  calculated  z-score.  (C)  Graph  represents  the  top  20  most  significantly  (z-score  >2  or  <-2)  altered  canonical  pathways  
identified  by  Ingenuity  Pathway  Analysis  (IPA)  with  corresponding  p-value  depicted  on  graph  bar.  Pathways  with  affiliated  
Ensembl  Gene  Stable  IDs  are  listed  in  Table  S3.  (D)  Bar  graph  highlights  the  percentage  of  up-  and  down-regulated  
genes  (with  corresponding  gene  number  displayed  within  bar)  in  the  top  20  significant  biological  processes,  cellular  
components,  and  molecular  functions  identified  by  Gene  Ontology  (GO)  term  analysis.  Corresponding  p-values,  Ensembl  
Gene  Stable  IDs  and  process  GO  accession  numbers  are  listed  in  Table  S4.  

  

Table  S1.  Related  to  Figures  1-4.  Demographic  information  of  normal  donors  
  
Donors  

Normal  
Controls  for  
Islet  
Perifusion  

Normal  
Controls  for  
Islet  
Transplants  

Age  
(years)  

Ethnicity/  
Race  

Gender    

BMI  

7  

Caucasian  

M  

26.8  

8  

Caucasian  

F  

16.1  

8  

African  American  

M  

17.2  

Respiratory  
arrest  
Intracerebral  
hemorrhage  
Anoxia  

9  
11  
19  
19  

Caucasian  
African  American  
Caucasian  
Caucasian  

M  
M  
M  
M  

15.5  
18.3  
20.1  
34.1  

Head  Trauma  
Anoxia  
Head  Trauma  
Head  Trauma  

Rita  Bottino  
Rita  Bottino  
Rita  Bottino  
IIDP  

20  
39  

African  American  
N/A  
Native  Hawaiian  
or  Other  Pacific  
Islander  

M  
F  

21.7  
28.2  

Head  Trauma  
N/A  

IIDP  
IIDP  

F  

25.4  

N/A  

IIDP  

Caucasian  

M  

22.7  

Anoxia  

Rita  Bottino  

F  

24.6  

Anoxia  

IIDP  

M  

27.5  

Head  Trauma  

IIDP  

M  
M  
M  

17.2  
19.3  
20.1  

Anoxia  
Head  Trauma  
Head  Trauma  

Rita  Bottino  
Rita  Bottino  
Rita  Bottino  

M  

21.2  

Anoxia  

Rita  Bottino  

M  

19.4  

Head  Trauma  

Rita  Bottino  

24  

Caucasian  
Hispanic/  
Latino  
Caucasian  

M  

35.5  

Head  Trauma  

Rita  Bottino  

55  

African  American  

M  

35.6  

Stroke  

Rita  Bottino  

26  

Hispanic/Latino  

F  

35.9  

Anoxia  

IIDP  

35  

Caucasian  

F  

23.6  

Anoxia  

IIDP  

49  

Caucasian  

F  

31.6  

Stroke  

IIDP  

50  

African  American  

M  

30.2  

Stroke  

IIDP  

55  

Caucasian  

M  

27.8  

Stroke  

IIDP  

53  
11  

Normal  
Control  for  
qRT-PCR  

20  
29  

Normal  
Controls  for  
Histology  

  

Normal  
Controls  for  
RNA-seq  

8  
10  
19  
19  
20  

Hispanic/  
Latino  
Hispanic/  
Latino  
African  American  
Caucasian  
Caucasian  

N/A  –  not  available;;  IIDP  –  Integrated  Islet  Distribution  Program  

  

Cause  of  
Death  

Tissue/Islet  
Source  
Rita  Bottino  
Rita  Bottino  
Rita  Bottino  

Table  S2.  Related  to  Figures  1-  4  and  Table  1.  DNA  sequencing  of  T1D  donors  for  variants  associated  with  monogenic  
diabetes      
dbSNP  ID  

MAF  

POLY  Score  

c.*9C>T  
c.963+2T>G  
c.963+7T>G  
c.403A>C  
c.1641+1G>C  
c.110C>T  
c.1347G>A  

Amino  Acid  
Change  
-  
-  
-  
p.Thr135Pro  
-  
p.Pro37Leu  
p.Ala449Ala  

rs79275829  
-  
-  
-  
rs35337543  
-  
rs201020486  

0.004  
0  
0  
0  
0.007  
0  
0  

0  
0  
0  
0  
0  
0.013  
0  

NM_000383.3  
NM_015120.4  
NM_005525.3  
NM_006726.4  
NM_001035256.1  
NM_015967.5  

c.1411C>T  
c.69_77del  
c.219+6G>A  
c.1536A>G  
c.706C>G  
c.1508A>G  

p.Arg471Cys  
p.Glu27_Glu29del  
-  
p.Ser512Ser  
p.Arg236Gly  
p.Tyr503Cys  

rs74203920  
-  
rs202219444  
-  
rs28932472  
rs371916399  

0.006  
0  
0  
0  
0.004  
0  

0.997  
0  
0  
0  
1  
0.004  

13  

NM_014832.3  

c.2913A>T  

p.Gly971Gly  

rs184774790  

0  

0  

BBS5  
BLM  
EIF2AK3  
HFE  
HNF4A  
PIK3R1  

2  
15  
2  
6  
20  
5  

NM_152384.2  

c.620G>A  

p.Arg207His  

rs35487251  

0.006  

0.833  

NM_000057.3  
NM_004836.5  
NM_000410.3  

c.2119C>T  
c.-201A>G  
c.845G>A  

p.Pro707Ser  
-  
p.Cys282Tyr  

rs146077918  
rs144057685  
rs1800562  

0.001  
0.005  
0.02  

0.018  
0  
0  

ALMS1  
FBN1  
GLP1R  
IFIH1  
MKS1  

2  
15  
6  
2  
17  

NM_175914.4  
NM_181523.2  
NM_015120.4  
NM_000138.4  
NM_002062.3  
NM_022168.3  
NM_017777.3  

c.1314C>G  
c.1176C>T  
c.12278G>A  
c.3294C>T  
c.59G>A  
c.1075G>C  
c.1528C>T  

p.Leu438Leu  
p.Phe392Phe  
p.Arg4093His  
p.Asp1098Asp  
p.Arg20Lys  
p.Val359Leu  
p.Arg510Trp  

-  
rs3730090  
-  
rs140587  
rs10305421  
-  
-  

0  
0.308  
0  
0.008  
0.007  
0  
0  

0  
0  
0  
0  
0.643  
0.996  
0.976  

Donor  

Gene  

Chr  

Transcript  

Nucleotide  

1  

AKT2  
CYP27B1  
CYP27B1  
FOXP3  
IFIH1  
SIRT1  
GLP1R  

19  
12  
12  
X  
2  
10  
6  

NM_001626.5  
NM_000785.3  
NM_000785.3  
NM_014009.3  
NM_022168.3  
NM_012238.4  
NM_002062.3  

AIRE  
ALMS1  
HSD11B1  
LRBA  
POMC  
PTPN22  

21  
2  
1  
4  
2  
1  

TBC1D4  

2  

3  

4  

5  

BLM  
CLEC16A  
HFE  
LRBA  
KCNK16  
LMNA  

15  
16  
6  
4  
6  
1  

NM_000057.3  
NM_015226.2  
NM_000410.3  
NM_006726.4  
NM_032115.3  
NM_005572.3  

c.2268A>G  
c.2945G>A  
c.187C>G  
c.7597A>C  
c.165G>A  
c.612G>A  

p.Lys756Lys  
p.Ser982Asn  
p.His63Asp  
p.Thr2533Pro  
p.Leu55Leu  
p.Leu204Leu  

rs146013879  
rs72650689  
rs1799945  
rs62346982  
rs138076469  
rs12117552  

0.001  
0.004  
0.084  
0.003  
0.002  
0.004  

0  
0.967  
0  
0.167  
0  
0  

6  

ABCC8  
BBS2  
EIF2AK3  
MKKS  
NTRK2  
VPS13B  

11  
16  
2  
20  
9  
8  

NM_000352.4  
NM_031885.3  
NM_004836.5  
NM_018848.3  
NM_006180.4  
NM_017890.4  

c.-430C>T  
c.155T>A  
c.-201A>G  
c.1015A>G  
c.483T>G  
c.8978A>G  

  -  
p.Val52Asp  
  -  
p.Ile339Val  
p.Thr161Thr  
p.Asn2993Ser  

-  
-  
rs144057685  
rs137853909  
rs199849633  
rs28940272  

0  
0  
0.005  
0.001  
0  
0.002  

0  
0.016  
0  
0.008  
0  
0.997  

7  

ABCC8  
AKT2  
CFTR  
LRBA  
VPS13B  

11  
19  
7  
4  
8  

NM_000352.4  
NM_001626.5  
NM_000492.3  
NM_006726.4  
NM_017890.4  

c.2176G>A  
c.1110G>T  
c.1521_1523del  
c.217-10del  
c.1832G>A  

p.Ala726Thr  
p.Pro370Pro  
p.Phe508del  
-    
p.Arg611Lys  

rs138687850  
rs41309435  
rs199826652  
-  
rs61754109  

0.001  
0.001  
0.006  
0  
0  

0.02634  
0  
0  
0  
0.02634  

8  

AKT2  
CYP27B1  
CYP27B1  
FXN  
IFIH1  

19  
12  
12  
9  
2  

NM_001626.5  
NM_000785.3  
NM_000785.3  
NM_000144.4  
NM_022168.3  

c.945G>A  
c.963+2T>G  
c.963+7T>G  
c.-7G>A  
c.1641+1G>C  

p.Glu315Glu  
-  
-  
-  
-  

rs150000674  
-  
-  
rs145006100  
rs35337543  

0.002  
0  
0  
0.011  
0.007  

0  
0  
0  
0  
0  

Chr  –  Chromosome,  MAF  –  Minor  allele  frequency;;  DNA  isolated  from  pancreatic  samples  of  T1D  donors  was  subjected  to  DNA  sequencing  covering  
coding  regions  and  splice  junctions  of  148  genes  associated  with  monogenic  diabetes.    
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